Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Study findings on breast cancer are outlined in reports from Washington University, Medical Department
June 25th, 2009
According to a study from the United States, "Several phosphoinositide 3-kinase (PI3K) catalytic subunit inhibitors are currently in clinical trial. We therefore sought to examine relationships between pharmacologic inhibition and somatic mutations in PI3K catalytic subunits in estrogen receptor (ER)-positive breast cancer, in which these mutations are particularly common." "RNA interference (RNAi) was used to determine the effect of selective inhibition of PI3K catalytic subunits, p110 alpha and p110 beta, in ER+ breast cancer cells harboring either mutation (PIK3CA) or gene amplification (PIK3CB). p110 alpha RNAi inhibited growth and promoted apoptosis in all tested...
Source: Women's Health Weekly (2009-06-25)
|
